bioRxiv preprint doi: https://doi.org/10.1101/2020.04.04.016642; this version posted April 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. A new synuclein-transgenic mouse model for early Parkinson's reveals molecular features of preclinical disease Diana M Hendrickx1,*,#, Pierre Garcia1,2,#, Amer Ashrafi1, Alessia Sciortino1, Kristopher J Schmit1, Heike Kollmus3, Nathalie Nicot4, Tony Kaoma5, Laurent Vallar6, Manuel Buttini1,*,$, Enrico Glaab1,$ 1 Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Belvaux, Luxembourg 2 Laboratoire National de Sant´e(LNS), Neuropathology Unit, Dudelange, Luxembourg 3 Department of Infection Genetics, Helmholtz Centre for Infection Research, Braunschweig, Germany 4 Quantitative Biology Unit, Luxembourg Institute of Health, Strassen, Luxembourg 5 Department of Oncology, Luxembourg Institute of Health, Strassen, Luxembourg 6 Genomics Research Unit, Luxembourg Institute of Health, Luxembourg, Luxembourg *
[email protected];
[email protected] # equal contributor $ equal contributor Abstract Understanding Parkinson's disease (PD) in particular in its earliest phases is important for diagnosis and treatment. However, human brain samples are collected post-mortem, reflecting mainly end stage disease. Because brain samples of mouse models can be collected at any stage of the disease process, they are useful to investigate PD progression. Here, we compare ventral midbrain transcriptomics profiles from α-synuclein transgenic mice with a progressive, early PD-like striatum neurodegeneration across different ages using pathway, gene set and network analysis methods.